EP. 1B: Advanced/Metastatic Prostate Cancer: Disease Overview, Treatment Strategies, and Unmet Needs
In this companion article, Judd W. Moul, MD, of Duke University Medical Center, shares expert insights into factors affecting treatment decisions in metastatic hormone-sensitive and castration-resistant prostate cancer.
EP. 1A: Treatment Overview: Metastatic Hormone-sensitive or Castration-resistant Prostate Cancer
In the first interview of the series, Judd W. Moul, MD, provides an overview of the management of mHSPC and mCRPC including key considerations in the use of the androgen deprivation therapy leuprolide with or without novel hormone therapy or chemotherapy.
Remaining Unmet Needs and Future Directions in Prostate Cancer Screening
Judd W. Moul, MD, FACS, wraps up by discussing remaining unmet needs and potential future improvements in imaging modalities for prostate cancer screening.
Recommended Management of the Profiled Patient
An expert urologic oncologist revisits a patient profile and discusses how he would have approached the patient’s prostate cancer screening process.
Real-World Use of an Exosome-Based Urine Biomarker Test
Judd W. Moul, MD, FACS, gives a real-world overview of how the exosome-based test is used in clinical practice.
Clinical Validity and Utility of an Exosome-Based Urine Biomarker Test
An overview of the clinical validity and utility of a urine-based, exosomal molecular test for prostate cancer screening and risk assessment.
Utilization and Timing of Biomarker Tests for Prostate Cancer
Judd W. Moul, MD, FACS, provides insight into the timing of biomarker testing in the prostate cancer screening process, and discusses which patients might benefit the most from testing.
Pre-Biopsy Biomarker Tests for Prostate Cancer Risk Assessment
Judd W. Moul, MD, FACS, introduces available blood- and urine-based biomarker tests for prostate cancer screening, and discusses how they might overcome limitations of commonly used modalities.
Modalities for Prostate Cancer Diagnosis, Grading, and Staging
A focused discussion on the use of tools such as digital rectal exam, prostate biopsy, and MRI in prostate cancer diagnosis, staging, and grading.
Early Detection of Prostate Cancer: Challenges and Strategies
Judd W. Moul, MD, FACS, reviews challenges of early detection of prostate cancer, and strategies to mitigate them.
Trends in Prostate Cancer Incidence and Severity
A commentary on increasing trends in prostate cancer incidence and how many patients typically present with severe disease.
Introduction: A 64-Year-Old Man with Elevated PSA Levels
Judd W. Moul, MD, FACS, introduces the patient profile and discusses typical characteristics of patients undergoing prostate cancer screening in his practice.
Real-world effectiveness and treatment adherence with apalutamide in nmCRPC
Judd W. Moul, MD discusses data on real-world effectiveness and treatment adherence of apalutamide in non-metastatic castration-resistant prostate cancer patients that was presented at the American Urological Association 2021 Annual Meeting.
UroView: The Role of Liquid Biomarkers for Early Detection of Prostate Cancer
This article features insights from David Albala, MD, and Judd W. Moul, MD, on using liquid biomarker-based testing for the early detection of prostate cancer.
Unmet Needs in the Early Detection of Prostate Cancer
Expert urologists remark on unmet needs in prostate cancer by emphasizing the importance of reaching under-served communities, addressing patient discomfort, increasing education about liquid biopsy testing, and standardizing prostate size assessment.
Algorithms for Diagnostic Testing in Prostate Cancer
Key opinion leaders in urology review factors to consider when selecting screening and risk-assessment tests for the diagnosis of prostate cancer including insurance coverage, commercial availability, and patient preference.
COVID-19: Telehealth and Compliance in Prostate Cancer
David Albala, MD and Judd W. Moul, MD consider the impact that COVID-19 has had on the clinical experience of patients with prostate cancer and share personal insights regarding telehealth and patient compliance.
Blood and Urine Liquid Biopsy Tests in Prostate Cancer
Two experts in the management of prostate cancer provide key insight into the value of blood and urine liquid biopsy tests when deciding whether to perform a prostate tissue biopsy.
Challenges of Using MRI When Diagnosing Prostate Cancer
Thought leaders in the management of prostate cancer build a discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort.
Screening Prostate Cancer with Blood and Urine Tests
Experts urologists, David Albala, MD and Judd W. Moul, MD, compare the utility of a variety of blood and urine tests for screening and diagnosing prostate cancer.
Risk Assessment in Prostate Cancer: The PSA Test
Key opinion leaders in urology provide an overview of the prevalence of prostate cancer and discuss the importance of screening and risk assessment tools like the Prostate-Specific Antigen (PSA) test.
Case 2: 64-Year-Old Man With Multifocal Prostate Cancer Post-IMRT
Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT.
Considerations for Tracer Selection to Assess Biochemical Recurrence in Prostate Cancer
Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection.
Imaging Modalities for Evaluating Biochemical Recurrence in Prostate Cancer
An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.
Case 1: 58-Year-Old Man 6 Months Post-Radical Prostatectomy
Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection.
Considerations for Initiating ADT After Biochemical Recurrence in Prostate Cancer
Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence.
Defining PSA Nadir After Definitive Therapy in Prostate Cancer
Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer.
Best Practices for Monitoring After Definitive Therapy in Prostate Cancer
Dr Judd Moul and colleagues discuss best practices for monitoring patients with prostate cancer after definitive therapy.
Rate of BCR in Prostate Cancer
Dr Raoul Concepcion leads a panel of experts in prostate cancer in setting the stage for case-based discussions of biochemical recurrence.
2 Clarke Drive Cranbury, NJ 08512